Estimates Revisions Zealand Pharma A/S OTC Markets
Stocks
ZLDPY
US98920Y1064
Biotechnology & Medical Research
|
Market Closed -
OTC Markets
13:57:04 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 8.670 USD | -2.03% |
|
-2.03% | -45.81% |
| 09-16 | Zealand Pharma A/S Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 11:30 AM | |
| 09-15 | Elvinix licenses diabetes portfolio from Zealand Pharma | FW |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Zealand Pharma A/S(ZEAL)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Zealand Pharma A/S(ZEAL)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Zealand Pharma A/S(ZEAL)
EBIT
Dividend / Share (DPS)
Data source:
Zealand Pharma A/S(ZEAL)
Cash or Net Debt
- Stock Market
- Stocks
- ZEAL Stock
- ZLDPY Stock
- Consensus Zealand Pharma A/S
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
